Research
Hormonal
Obesity increases the risk for Type 2 diabetes, hypertension, and cardiovascular disease.
Healthcare providers should prioritize weight management in patients with cardiovascular disease.
StrongSupportsmedium confidence
Obesity is known to increase the risk for Type 2 diabetes and hypertension, as well as the risk for overt cardiovascular (CV) disease, including myocardial infarction, heart failure, and stroke.
Why this rating
The claim is supported by established knowledge in the field.
Source
The cardiovascular effects of novel weight loss therapies
Muhammad Usman et al. · European Heart Journal · 2023
DOI 10.1093/eurheartj/ehad664
reviewCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →